期刊文献+

β-连环素在结肠腺癌中的异常表达及其与预后的关系 被引量:5

Clinical significance and prognostic value of β-catenin expression in colonic adenocarcinoma
下载PDF
导出
摘要 目的:检测β-连环素(β-catenin)在结肠腺癌组织中的异常表达情况,分析其临床意义及与预后的关系。方法:收集2000年6月至2004年6月实施根治性切除、临床资料及随访资料完整的52例结肠腺癌患者及20例癌旁正常结肠组织的石蜡组织切片,采用免疫组织化学方法检测β-catenin的表达情况,并分析其与临床因素和预后的关系。结果:20例正常癌旁组织中β-catenin均呈正常表达。52例结肠腺癌组织中β-catenin的异常表达率为71%,β-catenin的异常表达与患者的性别、年龄、肿瘤分化程度及血癌胚抗原(CEA)异常无关(P>0.05),与淋巴结转移及临床分期相关(P<0.05)。表达正常组患者术后生存期高于表达异常组患者,两者比较显著差异(P<0.05)。结论:β-catenin的异常表达与结肠腺癌淋巴结转移及肿瘤的临床分期有关,其异常表达可能是结肠癌预后不良的重要因素,可作为临床判断结肠腺癌患者预后的指标之一。 AIM:To observe the expression of β-catenin in colonic adenocarcinoma and to investigate its clinical significance and prognostic value. METHODS:The integrated clinical and follow -up data of 52 patients,who were undergone radical operation,were retrospectively analyzed from June 2000 to June 2004 in our hospital. The paraffin -embedded tissues of 52 colonic adenocarcinoma specimens and 20 cases of normal paraneoplastic colonic mucous tissues were detected for β-catenin expression by immunohistochemical method. The relationships between β-catenin and clinical variables and prognostic value were statistically analyzed. RESULTS:β-catenin was normally expressed in all 20 normal cases. In the cases of colonic adenocarcinoma,the abnormal expression rate of β-catenin was 71%. The abnormal expression of β-catenin did not correlated with gender,age,histological differentiation and blood CEA (P 0. 05),but it was correlated with lymph node metastasis and clinical stage (P 0. 05). The abnormal expression of β-catenin were also correlated with the postoperative survive time (P 0. 05). CONCLUSION:The abnormal expression of β-catenin is correlated with the lymph node metastasis and clinical stage,and the abnormal expression is an important adverse prognostic factor for survival in the patients with colonic adenocarcinoma. β-catenin may be a molecular prognostic marker in the patients with colonic adenocarcinoma.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2010年第5期928-930,共3页 Chinese Journal of Pathophysiology
基金 广东省医学科研基金资助项目(No.A2009356)
关键词 结肠肿瘤 Β-连环素 预后 Colonic neoplasms β-catenin Prognosis
  • 相关文献

参考文献9

  • 1Peifer M,Polakis P.Wnt signaling in oncogenisis and embryogenesis a look outside the nucleus[J].Science,2000,287(5458):1606-1609.
  • 2De Miglio MR,Virdis P,Calvisi DF,et al.Identification and chromosome mapping of loci predisposing to colorectal cancer that control Wnt/beta-catenin pathway and progression of early lesions in the rat[J].Carcinogenesis,2007,28(11):2367-2374.
  • 3高明,吕永添.结直肠癌组织中β-Catenin的异常表达及其意义[J].广东医学,2007,28(9):1478-1479. 被引量:1
  • 4陈徐艰,吴李明,徐小波,冯晓文,谢海洋,张珉,沈岩,王伟林,粱廷波,郑树森.生物学标记物应用于肝癌原位肝移植预后的研究[J].中国病理生理杂志,2008,24(2):311-314. 被引量:1
  • 5Chiang JM,Chou YH,Chen TC,et al.Nuclear beta-catenin expression is closely related to ulcerative growth of colorectal carcinoma[J].Br J Cancer,2002,86(7):1124-1129.
  • 6Wong NA,Pignatelli M.Beta-catenin a linchpin in colorectal carcinogenesis?[J].Am J Pathol,2002,160(6):389-401.
  • 7Horst D,Reu S,Kriegl L,et al.The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer[J].Cancer,2009,115(10):2063-2070.
  • 8吕文平,董家鸿,黄志强,王曙光,别平,石爽.β-catenin在肝细胞癌中的表达及其临床意义[J].解放军医学杂志,2008,33(5):563-565. 被引量:1
  • 9杨林,王金万,张弘刚,李玉升,崔成旭,黄镜,周爱萍,依荷芭丽.迟,石远凯.196例结肠癌术后辅助化疗疗效和预后因素分析[J].中国肿瘤临床,2009,36(7):368-371. 被引量:8

二级参考文献29

  • 1Maija H Zile.Abnormal β-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China[J].World Journal of Gastroenterology,2001,7(4):542-546. 被引量:22
  • 2吕文平,董家鸿,李晓武.组织芯片技术原位检测石蜡包埋肝细胞癌组织的研究[J].消化外科,2005,4(4):265-267. 被引量:2
  • 3赵东兵,高纪东,单毅,周志祥,袁兴华,吴健雄,邵永孚.结肠癌根治术后转移复发的特点及预后分析[J].中华胃肠外科杂志,2006,9(4):291-293. 被引量:36
  • 4Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer[J]. N Engl J Med, 2004, 350(23): 2343-2351.
  • 5de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC triM, inclliding survival, with a median follow-up of six years[J]. J Clin Oncol, 2007, 25(18S): 4007a.
  • 6Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage Ⅱ and Ⅲ colon cancer: results from NSABP c-07[J].J Clin Oncol, 2007, 25(16): 2198-2204.
  • 7Wolmark N, Wieand S, Kuebler PJ, et al. A phase Ⅲ trial comparing FULV to FULV + oxaliplatin ha stage Ⅱ or Ⅲ carcinoma of the colon: Survival results of NSABP Protocol c-07[J].J Clin Oncol, 2008, 26(15S): LBA4005a.
  • 8Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma[J].N Engl J Med, 1990, 322(6): 352-358.
  • 9Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic[J]. J Clin Oncol, 1989, 7(10): 1447-1456.
  • 10Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage Ⅲ colon carcinoma: a final report[J]. Ann Intern Med, 1995, 122(5): 321-326.

共引文献7

同被引文献28

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部